[go: up one dir, main page]

PE20070621A1 - 2-amino-7,8-dihidro-6h-pirido(4,3-d)pirimidina-5-onas - Google Patents

2-amino-7,8-dihidro-6h-pirido(4,3-d)pirimidina-5-onas

Info

Publication number
PE20070621A1
PE20070621A1 PE2006001177A PE2006001177A PE20070621A1 PE 20070621 A1 PE20070621 A1 PE 20070621A1 PE 2006001177 A PE2006001177 A PE 2006001177A PE 2006001177 A PE2006001177 A PE 2006001177A PE 20070621 A1 PE20070621 A1 PE 20070621A1
Authority
PE
Peru
Prior art keywords
pyrimidine
amino
pyrid
dihydro
methyl
Prior art date
Application number
PE2006001177A
Other languages
English (en)
Inventor
Timothy D Machajewski
Cynthia M Shafer
William Antonios-Mccrea
Barry H Levine
Maureen Mckenna
Kris Mendenhall
Baoqing Gong
John Dolan
Zhenhai Gao
Kristin Brinner
John Tulinsky
Dan Gu
Yasheen Zhou
X Michael Wang
Yi Xia
Brandon M Doughan
Christopher Mcbride
Daniel Poon
Paul A Barsanti
Xiaodong Lin
Abran Costales
Alice Rico
Nathan Brammeier
Teresa Pick
Paul A Renhowe
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of PE20070621A1 publication Critical patent/PE20070621A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/80—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D211/84—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen directly attached to ring carbon atoms
    • C07D211/86—Oxygen atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyridine Compounds (AREA)

Abstract

SE REFIERE A COMPUESTOS DE FORMULA I, DONDE Ra ES H, HALOGENO, HIDROXILO, TIOL, ENTRE OTROS; R ES H, ALQUILO C1-C6 SUSTITUIDO O NO, ALQUENILO C2-C6 SUSTITUIDO O NO, ENTRE OTROS; Rb ES CICLOALQUILO C3-C7 SUSTITUIDO O NO, CICLOALQUENILO C5-C7, ARILO SUSTITUIDO O NO, ENTRE OTROS. SON COMPUESTOS PREFERIDOS: (R)-2-AMINO-7-(2-(CICLOPENTILOXI)-4-FLUOROFENILO)-4-METILO-7,8-DIHIDROPIRIDO[4,3-d]PIRIMIDINA-5(6H)-ONA; (R)-2-AMINO-7-[5-(6-METOXI-PIRAZINA-2-ILO)-TIAZOL-4-ILO]-4-METILO-7,8-DIHIDRO-6H-PIRIDO[4,3-d]PIRIMIDINA-5-ONA; (S)-2-AMINO-7-(2-BROMO-4-FLUORO-FENILO)-6-[(S)-1-(4-METOXI-FENILO)-ETILO]-4-METILO-7,8-DIHIDRO-6H-PIRIDO[4,3d]PIRIMIDINA-5-ONA, ENTRE OTROS. TAMBIEN SE REFIERE A UNA COMPOSICION FARMACEUTICA Y A UN PROCEDIMIENTO DE PREPARACION. ESTOS COMPUESTOS SON INHIBIDORES DE HSP90 Y SON UTILES EN EL TRATAMIENTO DE ENFERMEDADES PROLIFERATIVAS CELULARES, VIRALES, AUTOINMUNE, CARDIOVASCULARES Y DEL SISTEMA NERVIOSO CENTRAL
PE2006001177A 2005-09-30 2006-09-28 2-amino-7,8-dihidro-6h-pirido(4,3-d)pirimidina-5-onas PE20070621A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US72279605P 2005-09-30 2005-09-30
US83688606P 2006-08-09 2006-08-09

Publications (1)

Publication Number Publication Date
PE20070621A1 true PE20070621A1 (es) 2007-09-06

Family

ID=37661234

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2006001177A PE20070621A1 (es) 2005-09-30 2006-09-28 2-amino-7,8-dihidro-6h-pirido(4,3-d)pirimidina-5-onas

Country Status (31)

Country Link
US (2) US7671059B2 (es)
EP (1) EP1928875B1 (es)
JP (2) JP5036002B2 (es)
KR (1) KR101311757B1 (es)
AR (1) AR058072A1 (es)
AT (1) ATE514694T1 (es)
AU (1) AU2006297124B2 (es)
BR (1) BRPI0616701A2 (es)
CA (1) CA2624253C (es)
CR (1) CR9846A (es)
CY (1) CY1112028T1 (es)
DK (1) DK1928875T3 (es)
EA (1) EA016152B1 (es)
EC (1) ECSP088324A (es)
GE (1) GEP20115231B (es)
HR (1) HRP20110655T1 (es)
IL (1) IL190446A0 (es)
JO (1) JO2783B1 (es)
MA (1) MA29885B1 (es)
ME (1) ME01952B (es)
MY (1) MY143604A (es)
NO (1) NO342258B1 (es)
NZ (1) NZ566914A (es)
PE (1) PE20070621A1 (es)
PL (1) PL1928875T3 (es)
PT (1) PT1928875E (es)
RS (1) RS51795B (es)
SM (1) SMP200800029B (es)
TN (1) TNSN08143A1 (es)
TW (1) TWI373471B (es)
WO (1) WO2007041362A1 (es)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CL2007002994A1 (es) * 2006-10-19 2008-02-08 Wyeth Corp Compuestos derivados heterociclicos que contienen sulfamoilo, inhibidores de hsp90; composicion farmaceutica; y uso para el tratamiento del cancer, tal como cancer de mama, de colon y prostata, entre otros.
CN101225083A (zh) * 2007-01-16 2008-07-23 北京摩力克科技有限公司 四氢喹唑啉酮类化合物及其用于制备治疗和预防病毒性疾病的药物的用途
GB2449293A (en) * 2007-05-17 2008-11-19 Evotec Compounds having Hsp90 inhibitory activity
AU2009208947B2 (en) * 2008-02-01 2014-02-06 Takeda Pharmaceutical Company Limited Oxim derivatives as HSP90 inhibitors
EP2334379A2 (en) 2008-09-26 2011-06-22 INSERM (Institut National de la Santé et de la Recherche Médicale) Host cell kinases as targets for antiviral therapies against hcv infection
CA2743722A1 (en) * 2008-11-28 2010-06-03 Novartis Ag Hsp90 inhibitors for therapeutic treatment
CN102227227B (zh) * 2008-11-28 2014-05-28 诺华股份有限公司 包含吡啶并[4，3-d]嘧啶衍生的HSP90抑制剂和HER2抑制剂的药物组合
JP2012510442A (ja) * 2008-11-28 2012-05-10 ノバルティス アーゲー Ｈｓｐ９０阻害剤の組合せ
AR075180A1 (es) * 2009-01-29 2011-03-16 Novartis Ag Formulaciones orales solidas de una pirido-pirimidinona
AR077405A1 (es) 2009-07-10 2011-08-24 Sanofi Aventis Derivados del indol inhibidores de hsp90, composiciones que los contienen y utilizacion de los mismos para el tratamiento del cancer
FR2949467B1 (fr) 2009-09-03 2011-11-25 Sanofi Aventis Nouveaux derives de 5,6,7,8-tetrahydroindolizine inhibiteurs d'hsp90, compositions les contenant et utilisation
BR112012010085B1 (pt) * 2009-10-29 2020-02-04 Genosco composto, quantidade terapeuticamente eficaz de um composto, formulação farmacêutica
WO2012104823A2 (en) 2011-02-04 2012-08-09 Novartis Ag Pyridopyrimidinone compounds in the treatment of neurodegenerative diseases
CN103857392A (zh) 2011-10-14 2014-06-11 诺华股份有限公司 用于治疗增生性疾病的2-甲酰胺环氨基尿素衍生物与Hsp90抑制剂的组合
ITTO20111013A1 (it) 2011-11-03 2013-05-04 Dac Srl Composti farmaceutici
CN103664938A (zh) * 2012-09-12 2014-03-26 山东亨利医药科技有限责任公司 含有嘧啶并环的syk抑制剂
WO2014074580A1 (en) 2012-11-07 2014-05-15 Novartis Ag Combination therapy
US9677907B2 (en) * 2013-03-14 2017-06-13 Itron Inc Intelligent receptacle
GB201306610D0 (en) * 2013-04-11 2013-05-29 Almac Discovery Ltd Pharmaceutical compounds
WO2015046498A1 (ja) 2013-09-30 2015-04-02 大鵬薬品工業株式会社 アザ二環式化合物を用いたがん併用療法
EP3189051A1 (en) * 2014-09-02 2017-07-12 Pierre Fabre Médicament Isoquinolinone derivatives useful in the treatment of cancer
KR20160035411A (ko) * 2014-09-23 2016-03-31 주식회사 오스코텍 LRRK2 (Leucine Rich Repeat Kinase 2) 키나제 억제제로서의 피리도피리미딘 유도체 화합물
KR101653560B1 (ko) * 2016-02-02 2016-09-12 한국화학연구원 신규한 화합물 또는 이의 약학적으로 허용가능한 염, 및 이를 유효성분으로 함유하는 인플루엔자 바이러스 감염으로 인한 질환의 예방 또는 치료용 약학적 조성물
RU2629599C1 (ru) * 2016-09-28 2017-08-30 Государственное бюджетное учреждение здравоохранения Московской области "Московский областной научно-исследовательский клинический институт им. М.Ф. Владимирского" (ГБУЗ МО МОНИКИ им. М.Ф. Владимирского) Способ химиолучевого лечения опухолей прямой кишки и анального канала
US11542299B2 (en) 2017-06-09 2023-01-03 Chugai Seiyaku Kabushiki Kaisha Method for synthesizing peptide containing N-substituted amino acid
JP7658971B2 (ja) 2020-06-26 2025-04-08 日本農薬株式会社 アリールテトラヒドロピリジン誘導体又はその塩類及び該化合物を含有する殺虫剤並びにその使用方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6165873A (ja) * 1984-09-07 1986-04-04 Mitsui Petrochem Ind Ltd ２−ピペラジノピリミジン誘導体
CA1307786C (en) 1984-12-14 1992-09-22 Keiichi Yokoyama Quinazoline derivatives and antihypertensive preparations containing same as effective components
IL85347A0 (en) 1987-02-11 1988-07-31 May & Baker Ltd Cyclic diones
NZ526961A (en) * 2001-02-12 2005-03-24 F 6-substituted pyrido-pyrimidines
DE102004018198A1 (de) 2004-04-15 2005-11-03 Merck Patent Gmbh Sulfonamide
WO2006045010A2 (en) 2004-10-20 2006-04-27 Resverlogix Corp. Stilbenes and chalcones for the prevention and treatment of cardiovascular diseases
US20100152206A1 (en) * 2005-01-07 2010-06-17 Ralph Mazitschek Bicyclic Dihydropyrimidines and Uses Thereof
KR20080006614A (ko) 2005-04-14 2008-01-16 노바티스 백신즈 앤드 다이아그노스틱스 인코포레이티드 증식 질환의 치료에 유용한 ｈｓｐ90 억제제인2-아미노-퀴나졸린-5-온

Also Published As

Publication number Publication date
CR9846A (es) 2008-08-01
AR058072A1 (es) 2008-01-23
NO20082069L (no) 2008-06-09
TWI373471B (en) 2012-10-01
NO342258B1 (no) 2018-04-30
US20070123546A1 (en) 2007-05-31
KR20080057318A (ko) 2008-06-24
CA2624253A1 (en) 2007-04-12
BRPI0616701A2 (pt) 2011-06-28
CY1112028T1 (el) 2015-11-04
NZ566914A (en) 2011-09-30
KR101311757B1 (ko) 2013-09-26
TNSN08143A1 (en) 2009-07-14
MA29885B1 (fr) 2008-10-03
ATE514694T1 (de) 2011-07-15
US7671059B2 (en) 2010-03-02
SMAP200800029A (it) 2008-05-07
MY143604A (en) 2011-06-15
JP2012158611A (ja) 2012-08-23
AU2006297124B2 (en) 2011-12-08
JP2009510108A (ja) 2009-03-12
ME01952B (en) 2011-12-31
EA200800992A1 (ru) 2008-10-30
TW200728304A (en) 2007-08-01
CA2624253C (en) 2015-06-16
EP1928875B1 (en) 2011-06-29
IL190446A0 (en) 2008-11-03
GEP20115231B (en) 2011-06-10
HRP20110655T1 (hr) 2011-10-31
RS51795B (en) 2011-12-31
HK1118823A1 (en) 2009-02-20
DK1928875T3 (da) 2011-10-03
JP5036002B2 (ja) 2012-09-26
JO2783B1 (en) 2014-03-15
PT1928875E (pt) 2011-09-06
WO2007041362A1 (en) 2007-04-12
EA016152B1 (ru) 2012-02-28
US20100004237A1 (en) 2010-01-07
AU2006297124A1 (en) 2007-04-12
ECSP088324A (es) 2008-04-28
SMP200800029B (it) 2008-05-07
PL1928875T3 (pl) 2011-11-30
EP1928875A1 (en) 2008-06-11

Similar Documents

Publication Publication Date Title
PE20070621A1 (es) 2-amino-7,8-dihidro-6h-pirido(4,3-d)pirimidina-5-onas
PE20220592A1 (es) Inhibidores de la autofagia de heteroarilaminopirimidina amida y metodos de uso de estos
PE20151249A1 (es) Derivados de pirazolopirimidina como inhibidores de jak quinasas
MX2020013817A (es) Compuestos de naftiridinona sustituidos utiles como activadores de celulas t.
PE20050081A1 (es) Nuevas imidazopirazinas como inhibidores de cinasas dependientes de ciclinas
EA201991399A1 (ru) Аминотриазолопиридиновые соединения и их применение в лечении рака
PE20090058A1 (es) Compuestos carboxamida heterociclicos como inhibidores de la actividad akt
PE20040999A1 (es) Nuevas pirazolopirimidinas como inhibidores de cinasas dependientes de ciclinas
MX2010003927A (es) Derivados de pirrolo [2,3-d] pirimidina como inhibidores de proteinas cinasas b.
LU93078I2 (fr) Combimetinib, éventuellement sous toute forme protégée par le brevet de base, y compris les sels et solvates pharmaceutiquement acceptables, en particulier hémifumarate de cobimetinib
PE20090902A1 (es) Combinacion de un antimitotico e inhibidor de aurora quinasa como agentes anticancerigenos
PE20070723A1 (es) Imidazopirazinas como inhibidores de quinasas dependientes de ciclina
CY1113642T1 (el) Γεφυρωμενες δικυκλικες ετεροαρυλ υποκατεστημενες τριαζολες, χρησιμες ως αναστολεις της axl
SV2008002969A (es) Derivados de pirimidina para el tratamiento del crecimiento celular anormal
GB0305152D0 (en) Organic compounds
SV2005001918A (es) Metodos para preparar derivados 7-(b-d-ribofuranosilo sustituido en 2')-4 (nr2r3)-5(etin-1-ilo sustituido)-pirrol[2,3-d]pirimidina
CL2007001710A1 (es) Compuestos derivados de amino-pirazolopiridina sustituidos; metodo de preparacion; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como tumores, artritis reumatoide, enfermedades de crecimiento vascular desregulado, entre otras.
ECSP077324A (es) Amidas bicíclicas como inhibidores de cinasa
SV2007002202A (es) Inhibidores de la arn polimerasa dependiente de arn del virus de la hepatitis c y composiciones y tratamientos que los usan ref. pc32310a
PE20070752A1 (es) Triazolopiridazinas como moduladores de quinasa
MXPA05007462A (es) Derivados de pirrolopiridazina.
PE20110419A1 (es) Compuestos de pirrolo-pirimidina como inhibidores de cdk
CY1114148T1 (el) Γεφυρωμενες δικυκλικες αρυλο- και γεφυρωμενες δικυκλικες etepoapyλo-υποκατεστημενες τριαζολες χρησιμες ως αναστολεις toy axl
EA201790995A1 (ru) ЗАМЕЩЕННЫЕ ПИРАЗОЛО[1,5-a]ПИРИМИДИНЫ И ИХ ПРИМЕНЕНИЕ ПРИ ЛЕЧЕНИИ ЗАБОЛЕВАНИЙ
EA200501332A1 (ru) Производные пиримидин-4-она и их применение в качестве модуляторов киназы p38

Legal Events

Date Code Title Description
FG Grant, registration
FD Application declared void or lapsed